TY - JOUR T1 - Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) JF - medRxiv DO - 10.1101/2020.09.16.20194324 SP - 2020.09.16.20194324 AU - Sara A. Hurvitz AU - Jennifer L. Caswell-Jin AU - Katherine L. McNamara AU - Jason J. Zoeller AU - Gregory R. Bean AU - Robert Dichmann AU - Alejandra Perez AU - Ravindranath Patel AU - Lee Zehngebot AU - Heather Allen AU - Linda Bosserman AU - Brian DiCarlo AU - April Kennedy AU - Armando Giuliano AU - Carmen Calfa AU - David Molthrop AU - Aruna Mani AU - Hsiao-Wang Chen AU - Judy Dering AU - Brad Adams AU - Eran Kotler AU - Michael F. Press AU - Joan S. Brugge AU - Christina Curtis AU - Dennis J. Slamon Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/18/2020.09.16.20194324.abstract N2 - In this neoadjuvant trial (TRIO-US B07), participants with early-stage HER2-positive breast cancer (N=128) were randomized to receive trastuzumab (T), lapatinib (L), or both (TL) as HER2-targeted therapy, with each participant given one cycle of this designated anti-HER2 therapy alone followed by six cycles of standard combination chemotherapy with the same anti-HER2 therapy. We observed similar pathologic complete response (pCR) rates between T and TL, and a lower pCR rate with L. Higher-level amplification of HER2 and hormone receptor-negative status were associated with a higher pCR rate. Higher pre-treatment immune infiltrate trended toward higher pCR rate in T-treated groups, and greater HR expression correlated with lower immune infiltrate. Large shifts in tumor, immune, and stromal gene expression occurred after one cycle of HER2-targeted therapy. In contrast to pCR rates, the L-containing arms exhibited greater proliferation reduction than T at this timepoint. Immune expression signatures increased in all arms after one cycle of HER2-targeted therapy, decreasing again by the time of surgery. Our results inform approaches to early assessment of sensitivity to anti-HER2 therapy and shed light on the role of the immune microenvironment in response to HER2-targeted agents.Competing Interest StatementSH received contracted research and medical writing assistance from Ambrx, Amgen, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, Puma, Radius, Sanofi, Seattle Genetics, and Dignitana. AP received institutional research support from Genentech, AstraZeneca, Immunomedics, Nektar, and Macrogenics. LB received honoraria from and/or was on the speaker bureau for AstraZeneca, Pfizer, Merck, Puma, Novartis, GlaxoSmithKline, Amgen, Johnson & Johnson, Genentech/Roche, Sandoz, Dendreon, and Genomic Health, and performed consulting work for Integra Connect and Anthem Blue Cross. AM is employed by Genentech/Roche and owns stock in Roche. MP received research support from Cepheid, was on the Scientific Advisory Board and received research support from Eli Lilly, Zymeworks, and Novartis, was a consultant for and received research support from Puma, and was on the Scientific Advisory Board for Biocartis. CC is a scientific advisor to GRAIL and reports stock options as well as consulting for GRAIL and Genentech. DS received research funding from Pfizer, Novartis, Syndax, Millenium Pharmaceuticals, Aileron Therapeutics, Bayer, and Genentech, owned stock in Biomarin, Amgen, Seattle Genetics, and Pfizer, served on the Board of Directors for BioMarin, and performed consulting/advisory board work for Eli Lilly, Novartis, Bayer, and Pfizer. JC, KM, JZ, GB, RD, RP, BD, AK, AG, CCa, DM, HC, JD, BA, EK, and JB have no conflicts of interest to report.Clinical TrialNCT0076947Funding StatementFunding for the clinical trial came from grants from Sanofi aventis and GlaxoSmithKline. SH was supported in part by NCI/NIH CA016042 as well as the Marni Levine Memorial Research Award. JLC was supported by a Damon Runyon Physician-Scientist Training Award and a Susan G. Komen Postdoctoral Fellowship Award (PDR17481769). KLM was supported by an award from the National Cancer Institute at the National Institutes of Health (F30CA239313-02). Funding for the molecular analyses was supported in part by an award from the National Cancer Institute at the National Institutes of Health (R01CA182514) to CC and an award from the Breast Cancer Research Foundation to CC. Funding for the immunohistochemistry analysis was supported in part by a Department of Defense Breast Cancer Research Fellowship Award, Award Number W81XWH-11-1-0572 (JJZ) and by a StandUp To Cancer-American Association for Cancer Research Dream Team Translational Cancer Research Grant, Grant Number SU2C-AACR-DT0409 (JSB). The funding sources had no role in the design of the study nor any role in the analysis and interpretation of data or decision to submit results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following institutional review boards approved the study protocol: UCLA, Olive View, and Western. The Stanford University institutional review board also approved the gene expression analyses.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw expression data are deposited in GEO (GSE130788). ER -